Associated Papers
Comparative analysis of web-based programs for single amino acid substitutions in proteins.
Choudhury A et al.
Plos One, 2022
35507592 (PubMed )
Supplement: pone.0267084.s001.xlsx › HRAS
The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
Nakhaeizadeh H et al.
Plos One, 2016
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.
Smith SC et al.
Cancer Research, 2012
Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.
Gremer L et al.
Human Molecular Genetics, 2010
Rassf family of tumor suppressor polypeptides.
Avruch J et al.
The Journal of Biological Chemistry, 2009
A cross-talk between oncogenic Ras and tumor suppressor PTEN through FAK Tyr861 phosphorylation in NIH/3T3 mouse embryonic fibroblasts.
Bahk YY et al.
Biochemical and Biophysical Research Communications, 2008
Synergistic activation of the murine gastrin promoter by oncogenic Ras and beta-catenin involves SMAD recruitment.
Chakladar A et al.
Biochemical and Biophysical Research Communications, 2005
Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells.
Pattingre S et al.
The Journal of Biological Chemistry, 2003
Differential structural requirements for interaction of Ras protein with its distinct downstream effectors.
Akasaka K et al.
The Journal of Biological Chemistry, 1996
Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation.
Drugan JK et al.
The Journal of Biological Chemistry, 1996
Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.
Michailidou C et al.
Disease Models & Mechanisms, 0
Select a paper to view details